The dual orexin receptor antagonist suvorexant, already approved for insomnia, is emerging as a candidate for something broader: modifying the course of Alzheimer’s disease by simultaneously improving sleep and targeting the neurodegenerative cascade itself.
A review published in the Journal of Alzheimer’s Disease synthesizes the evidence linking the orexin system to Alzheimer’s pathophysiology and argues that suvorexant occupies a unique position, a sleep drug with potential disease-modifying properties.
Key points
Sleep disruption is not merely a symptom of Alzheimer’s disease but an active aggravator. Poor sleep impairs glymphatic clearance of amyloid-beta and tau, disrupts synaptic plasticity, and fuels neuroinflammation. The orexin system, which regulates arousal and wakefulness, sits at the intersection of these processes: overactive orexin signaling is implicated both in insomnia and in the accumulation of Alzheimer’s pathology.
Suvorexant, by blocking orexin receptors OX1R and OX2R, does more than promote sleep. Preliminary studies suggest it may:
- Reduce amyloid and tau accumulation
- Enhance synaptic activity
- Lower neuroinflammation
Recent clinical trials in older adults with mild cognitive impairment or early-stage Alzheimer’s have shown improvements in sleep quality alongside safety and tolerability. Some data hint at cognitive benefits as well, though the authors caution that longer-term outcomes are needed.
Why it matters
Current Alzheimer’s treatments target amyloid or tau directly with mixed results. Suvorexant offers a parallel route: intervene on sleep disruption, a modifiable risk factor, and potentially slow the underlying pathology through the orexin pathway. If confirmed in prospective trials, this would reposition a well-characterized insomnia drug as a dual-purpose therapeutic for one of the most challenging neurodegenerative diseases.
Limits
The review synthesizes early-stage and preclinical evidence. Most of the mechanistic data come from animal models or small human studies. Large randomized trials with cognitive endpoints and biomarker confirmation (amyloid PET, CSF tau) are still needed.
Bottom line
Suvorexant targets both the symptom (poor sleep) and a potential driver (orexin-driven pathology) of Alzheimer’s disease. The next few years of clinical data will determine whether this dual action translates into meaningful cognitive preservation.
Source
Abbasi AA, Norouziyan F, Moradikor N. Role of suvorexant in Alzheimer’s disease: Targeting sleep, orexin signaling, and disease pathophysiology. J Alzheimers Dis. 2026 Jun 18. DOI: 10.1177/13872877261461161. PMID: 42312432.